Drugs / XC130-A10H
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04043338 | Aug 2019 → Jan 2022 | Parkinson disease | Xoc Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XC130-A10H | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04043338 ↗ |
| Route | Oral | “In each cohort, subjects will receive a single oral dose of XC130-A10H or matching placebo on Day 1.” NCT04043338 ↗ |